Dedicated to making life better for people living with genetic diseases

Developing novel gene therapies by using lentiviral vector delivery platforms

Pursuing multiple indications in parallel by switching gene targets to create optimal therapies for a broad range of genetic diseases

"We are building a leading lentiviral-based cell and gene therapy company using our versatile dual technology platform and in-house manufacturing capabilities to advance development of potentially transformative therapies for patients and families seeking relief from devastating genetic diseases."

Matthew Gantz, President and Chief Executive Officer

Unlocking the potential of lentiviral vector delivery platforms

Using ex vivo and in vivo technologies to pursue multiple indications

What's New

Press Release
Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline  

Funding expected to provide sufficient capital for completion of Phase 3 trial for ex vivo product candidate for recessive dystrophic epidermolysis bullosa

Read More
Press Release
Castle Creek Biosciences Acquires Novavita Thera to Expand Innovative Cell and Gene Therapy Platform

Company adds in vivo capabilities to existing ex vivo approach for development of novel gene therapies

Read More
Press Release
Castle Creek Biosciences Awarded FDA Orphan Products Development Grant to Support DeFi-RDEB, a Pivotal Phase 3 Study of FCX-007 Investigational Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

RDEB is a devastating, rare genetic blistering disease with no FDA-approved treatments currently available

Read More
Press Release
Castle Creek Biosciences Expands its Innovative Gene Therapy Platform for Rare Genetic Connective Tissue Disorders through Research Collaboration with Mayo Clinic

Research to focus on osteogenesis imperfecta and classical Ehlers-Danlos syndrome, debilitating disorders with no FDA-approved treatments

Read More